MARKET

ADRO

ADRO

Aduro Biotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.350
+0.060
+4.65%
After Hours: 1.310 -0.04 -2.96% 16:00 09/16 EDT
OPEN
1.280
PREV CLOSE
1.290
HIGH
1.350
LOW
1.270
VOLUME
216.61K
TURNOVER
--
52 WEEK HIGH
7.64
52 WEEK LOW
1.150
MARKET CAP
108.19M
P/E (TTM)
-1.1737
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ADRO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ADRO News

  • Stocks That Hit 52-Week Lows On Wednesday
  • Benzinga.09/04 15:39
  • Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
  • GlobeNewswire.09/04 13:30
  • The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books
  • Benzinga.09/04 11:08
  • Aduro Biotech to Present at the H.C. Wainwright 21st Annual Global Investment Conference
  • GlobeNewswire.09/03 21:05

More

Industry

Biotechnology & Medical Research
+0.95%
Pharmaceuticals & Medical Research
-0.16%

Hot Stocks

Name
Price
%Change

About ADRO

Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. Its LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers. Its LADD product candidate is CRS-207, which is being developed as a treatment for multiple indications, including mesothelioma, ovarian and gastric cancers. ADU-214 and ADU-741 are product candidates in development for lung and prostate cancers, respectively.
More

Webull offers Aduro BioTech Inc (ADRO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.